Observational studyMedicine2026
Efficacy and safety of apixaban versus warfarin in new-onset atrial fibrillation post coronary artery bypass grafting: A retrospective cohort study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New-onset postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, especially coronary artery bypass grafting (CABG), affecting up to 40% of patients, and is associated with increased risks of thromboembolic events and prolonged hospital stays. Traditionally, warfarin has been the standard anticoagulant for stroke prevention in atrial fibrillation. However, it requires regular international normalized ratio monitoring. Direct comparisons between apixaban and warfarin in the CABG population remain scarce. This study aimed to compare the effectiveness and safety of apixaban versus warfarin in patients with POAF after CABG. A retrospective observational cohort study was conducted at King Abdulaziz Medical City, Riyadh, from January 1, 2017, to December 31, 2023. Eligible patients aged 18 and older who developed new-onset POAF and received apixaban or warfarin within 7 days postsurgery were included. The primary outcome was the incidence of thromboembolic events, while the secondary outcomes were safety outcomes, including bleeding complications. Out of 1277 records, 143 patients met the inclusion criteria. The incidence of thromboembolic events within 90 days was slightly lower in the apixaban group (2.0%) compared to warfarin (7.0%), though not statistically significant (P = .137). Major bleeding events occurred in 6.0% of patients on apixaban and 7.0% on warfarin (P = .825), and minor bleeding rates were also not statistically different, with 7.0% for apixaban and 11.6% for warfarin (P = .360), indicating no difference in safety profiles. Apixaban and warfarin demonstrated similar efficacy in preventing thromboembolic events and comparable safety regarding bleeding complications in patients with POAF following CABG, supporting apixaban as a reasonable alternative in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.